Phase 0 of CBS004 in SSc

Description

The overall aim of this sub-study is to prepare for a Phase 1 clinical trial for CBS004 in SSc. In our proposal and Phase 0 study, we will further investigate CBS004’s ability to inhibit IFN production by patient-derived pDC. We will also look at the antibody’s ability to affect TNF and IL-6 secretion. As a preclinical model, we will assess the antibody’s ability to inhibit the IFN response within patient skin biopsies stimulated by supernatant from autologous TLR-stimulated PBMC-supernatant. All the experiments will be run alongside a commercially available BDCA2-ab for comparison. The results of the experiments proposed here will complete the preclinical data set for CBS004.

Downloads

annrheumdis-2020-218439_anonymous.pdf